Indication

Acquired thrombocytopenia

Acquired thrombocytopenia is a hematologic condition defined by an abnormally low circulating platelet count—typically below 150,000 per microliter—that develops postnatally rather than from an inherited genetic defect. Read more about Acquired thrombocytopenia

318 drugs 159 manufacturers

Advertisement

Drugs that treat it

Common Acquired thrombocytopenia therapies.

Showing 154–162 of 318 drugs

Filter & compare in the drug finder →Opens the drug finder with Acquired thrombocytopenia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Acquired thrombocytopenia.

Acquired thrombocytopenia is a hematologic condition defined by an abnormally low circulating platelet count—typically below 150,000 per microliter—that develops postnatally rather than from an inherited genetic defect.

Affecting both pediatric and adult populations, it arises through diverse pathophysiologic mechanisms, including impaired bone marrow megakaryopoiesis, accelerated peripheral destruction, abnormal consumption, or splenic sequestration.

Etiologies encompass immune-mediated destruction, drug reactions, nutritional deficiencies, severe infections, and thrombotic microangiopathies.

Clinically, affected individuals may remain asymptomatic or present with mucocutaneous bleeding, petechiae, ecchymoses, and an increased risk of severe hemorrhage depending on the degree of platelet reduction.

Personalize your experience

Follow Acquired thrombocytopenia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it